REGN - 4D Molecular Therapeutics' 4D-150 Phase 2 Data Met Investor Expectations Analyst Boosts Forecast | Benzinga
Monday, 4D Molecular Therapeutics (NASDAQ:FDMT) released interim data from the Phase 2 PRISM clinical trial evaluating intravitreal 4D-150 in wet age-related macular degeneration (wet AMD) patients.
A single intravitreal dose of 4D-150 demonstrated favorable safety results through the data cutoff date.
BMO Capital Markets says the 4D-150 Phase 2 results met investor expectations.
In the foreseeable future, 4D Molecular Therapeutics’ gene therapy platform, along with the management’s track record of success, is anticipated to achieve success in treating various medical conditions such as diabetic macular edema, geographic atrophy, cystic fibrosis, and Alpha-1 antitrypsin deficiency, mirroring the accomplishments seen in wet Age-Related Macular Degeneration.
Short to medium-term prospects include potential announcements related to data, partnerships, ...